Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses
AssigneeFeynman Labs, LLC
InventorsCarl Johan Freer, Richard Kaszynski, Alessandro Gadotti
Life of this patent
Estimating the term…
Abstract
A method for treating an early-stage microbial infection comprising determining whether a subject exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and, if the subject is infected with the coronavirus, administering an antimicrobial agent is provided herein.
Claims12
A method for treating an early-stage infection by a virus in a subject comprising the steps of:
- obtaining a sample from the subject,
- providing the sample to a lateral flow assay,
- determining whether the subject is infected with the virus based on the results of the lateral flow assay, and
- if the subject is determined to be infected with the virus, administering to an antiviral agent and an antiparasitic agent the subject,
- wherein the subject has been exposed to the virus, is suspected of having been exposed to the virus, or has been in contact with a person exposed to or suspected of being exposed to the virus,
- wherein the antiviral agent is selected from the group consisting of favipiravir, favipiravir-RTP, remdesivir, and molnupiravir and the antiparasitic agent is ivermectin, and
- wherein the virus is SARS-CoV-2.
A method for treating a subject having an early-stage viral infection comprising administering to the subject a combination of an antiviral agent and an antiparasitic agent,
- wherein the early-stage viral infection is determined by a lateral flow assay,
- wherein the antiviral agent is selected from the group consisting of favipiravir, favipiravir-RTP, remdesivir, and molnupiravir and the antiparasitic agent is ivermectin, and
- wherein the virus is SARS-CoV-2.
Dependencies are inferred from the claim text.